Journal
ANTICANCER RESEARCH
Volume 41, Issue 2, Pages 1055-1062Publisher
INT INST ANTICANCER RESEARCH
DOI: 10.21873/anticanres.14862
Keywords
Salvage therapy; chemotherapy; colorectal cancer; cohort study
Categories
Ask authors/readers for more resources
This study showed that chemotherapy after regorafenib or TFTD was associated with prolonged overall survival in advanced CRC patients. Further research is needed to determine the appropriate treatment choice for these patients.
Background/aim: This study aimed to describe the chemotherapy effects after trifluridine/tipiracil (TFTD) and/or regorafenib treatment in colorectal cancer (CRC) patients. Patients and Methods: Patients receiving regorafenib or TFTD for metastatic CRC during 2013-2018 were selected and divided into two groups: one with additional chemotherapy after regorafenib or TFTD (CTX group) and one without additional chemotherapy (Non-CTX group). Patients were followed up from a landmark point (90 days from the last day of administration of regorafenib or TFTD). We compared overall survival (OS) between the groups. Results: The median OS was 7.7 months in the CTX group and 4.1 months in the non-CTX groups. Several sensitivity analyses did not negate the survival advantage detected in the CTX group. Conclusion: The chemotherapy after regorafenib or TFTD was associated with prolonged OS in advanced CRC patients. Further study is required to determine appropriate treatment choice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available